Full-Time

Quality Engineer

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$85k - $95k/yr

+ Annual Bonus Incentive

Wheat Ridge, CO, USA

In Person

Occasional travel may be required.

Bachelor's

Category
Manufacturing Quality & Test (1)
Required Skills
Risk Management
Data Analysis

Get referred to LivaNova

See people who can refer or advise you

Requirements
  • Minimum related work experience of 1-3 years in Class II/III medical device manufacturing or related regulatory industry.
  • Knowledge of regulatory requirements (e.g., FDA, ISO 13485) as required for the position.
  • Ability to analyze and problem-solve with CAPA experience.
  • Must have proficiency with quality tools such as flowcharts, statistical data analysis, mathematical reasoning.
  • Ability to work within a changing environment.
  • Ability to work with a wide variety of personnel on all levels and utilize constructive confrontation.
  • Sitting 60-80%, standing & walking 20-40%
  • Repetitive work on computer 80%
  • Oral and written comprehension.
  • Must be able to work in a clean room environment and tolerate chemical odors.
  • Must be able to work in a lab environment and tolerate the smell and sight of blood.
  • Must be willing to take on related duties as required in support of company and departmental objectives.
  • Occasional travel may be required.
  • Bachelor’s Degree in Technical and Scientific disciplines (Engineering, Physics, Chemistry, and Biology)
Responsibilities
  • Supports Quality Management for executing the quality engineering activities related to the design and manufacture of the products in compliance with the Quality Management System requirements and the regulations of the countries where the franchise distributes and sells products.
  • Collect and critically analyze data and take disposition decisions on nonconforming products identified in production.
  • Lead proper investigation to identify the causes of components / product failures (nonconforming products from production and complaints)
  • Generate the evaluation of the risk posed by the observed NC on products already distributed (Health Hazard Evaluation) to help management determine if Stop Shipment and/or Field Action is initiated.
  • Lead CAPA projects and trend data to identify opportunities for future CAPA.
  • Whenever applicable support external manufacturers of semi-finished and finished products in the management of any detected nonconformities.
  • May notify suppliers of any non-conformance related to purchased material and evaluate corrective actions consistency versus internal controls.
  • Establishes product quality control inspections/plans
  • Reviews process validation planning, protocols and reports
  • Perform preliminary review of the change impact assessment to confirm that quality requirements are met
  • Establish and maintain Risk Management files
  • Collaborates in the investigations into the cause of V&V failures
  • Identify opportunities for quality improvements in the production area and lead improvement plans
  • Daily management of the assigned complaint handling activities.
  • Customer-related processes involving use of the device.
  • Complaint evaluations and investigations.
  • Provides support for timely analysis to meet Customer Quality complaint and MDR reporting quality metrics.
  • Leads effective meetings, conducts presentations, establishes quality records.
  • Develops effective relationships with internal personnel and external stakeholders to assist customers and drive the resolution of customer complaints
Desired Qualifications
  • ASQ Certified Quality Engineer or other ASQ Certifications is a plus.
  • Experience with MDSAP and Medical Device Requirements is a plus.

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 10.8% to $390.6 million, with raised guidance.
  • OSPREY and CORE-VNS data strengthen payer and physician adoption for epilepsy and sleep apnea.
  • CMS coverage pursuit for treatment-resistant depression expands VNS reimbursement upside after 2026.

What critics are saying

  • A $400 million litigation payment lands in third quarter 2026, crushing free cash flow.
  • Cardiopulmonary growth depends on third-party components, constraining Essenz scaling through 2026.
  • If aura6000 adoption stalls, LivaNova lacks another large-growth engine beyond aging cardiac franchises.

What makes LivaNova unique

  • Aura6000 is first U.S.-approved HGNS device without CCC warning or DISE requirement.
  • Essenz heart-lung machines keep winning placements, especially Europe and China since August 2026.
  • LivaNova pairs neuromodulation, cardiopulmonary, and analytics partnerships like CoreInsights for Essenz.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Jun 16th, 2026
LivaNova's PolySync programming achieves 84.5% response rate in obstructive sleep apnoea study

LivaNova has announced that its PolySync programming algorithm achieved an 84.5% cumulative response rate in patients with moderate to severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation. The findings were presented at SLEEP 2026 by lead author Alan Schwartz. The results build on LivaNova's OSPREY trial, which reported a 65% responder rate after 12 months. In the PolySync substudy, patients who initially did not respond underwent reprogramming using simultaneous-contact stimulation, converting most into responders and significantly improving outcomes. The approach was well tolerated with no serious adverse events. PolySync will be available with LivaNova's commercial product. The company is preparing its next-generation obstructive sleep apnea device for FDA submission in the second half of 2026, featuring MRI compatibility and rechargeable battery technology.

Business Wire
Jun 11th, 2026
Jette Nygaard-Andersen joins LivaNova board as medtech company reshuffles directors

LivaNova, a medical technology company, has appointed Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on 10 June. Nygaard-Andersen currently chairs Coloplast A/S, a Danish medical device company, and previously served as CEO of Entain plc and in senior roles at Modern Times Group AB. The appointment coincides with Dr Sharon O'Kane stepping down after 10 years on the board. Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, whilst Peter Wilver assumes leadership of the Compensation and Human Capital Management Committee. LivaNova develops medical solutions for neurological and cardiac conditions, employs approximately 3,300 people, and operates in over 100 countries.

Yahoo Finance
May 6th, 2026
LivaNova posts 10% organic growth in Q2 driven by cardiopulmonary momentum and neuromodulation gains

LivaNova reported 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance across all regions. The company also delivered operating margin expansion and strong cash generation. The company announced key clinical milestones, including long-term results from the CORE-VNS study showing an 80% median seizure reduction at 36 months for focal onset seizures and 95% for focal to bilateral tonic-clonic seizures in drug-resistant epilepsy patients. LivaNova initiated the process with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression patients, supported by five peer-reviewed publications from the RECOVER study. The company's obstructive sleep apnea programme remains in FDA review, with management expressing confidence in its proximal hypoglossal nerve stimulation technology.

Yahoo Finance
May 6th, 2026
LivaNova posts 13% organic revenue growth in Q3, driven by cardiopulmonary surge and epilepsy gains

LivaNova reported 13% organic revenue growth in Q3 2025, driven by strong performance in cardiopulmonary and epilepsy businesses. The cardiopulmonary segment generated $203 million in revenue, up 16% year-over-year, with heart-lung machine revenue growing over 20%. The company saw accelerated placements of its Essenz heart-lung machines, with most installations in developed markets. LivaNova launched Essenz in China, its second-largest market, in August, with positive early feedback. However, expansion remains constrained by third-party component supply despite progressing manufacturing capacity plans. LivaNova unveiled a refreshed brand identity and new strategic framework, which will be detailed at its investor day on 12 November. The company is focusing on near-term performance whilst investing in core businesses and developing programmes for obstructive sleep apnoea.

Yahoo Finance
May 6th, 2026
LivaNova beats Q1 expectations with $362.3M revenue but shares slip 2% on cautious guidance

LivaNova reported first-quarter results that exceeded Wall Street expectations, but shares fell more than 2% in premarket trading as investors reacted cautiously to guidance. The medical technology company posted adjusted earnings per share of $0.98, beating analyst estimates of $0.90, whilst revenue reached $362.3 million, surpassing the $346.06 million consensus. The company raised its full-year 2026 revenue growth guidance to 7.0%–8.0% on a constant-currency basis, up from 6.0%–7.0% previously. Adjusted diluted EPS guidance increased to $4.20–$4.30 from $4.15–$4.25. However, the $4.25 midpoint only marginally exceeded analyst consensus of $4.21. Revenue growth was driven by the Cardiopulmonary division, which rose 18.3% to $208.7 million, and Neuromodulation, which climbed 9.3% to $151.8 million.